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Hyperphosphatemia is an inevitable consequence of end-
stage chronic kidney disease and is present in the majority of
dialysis patients. Hyperphosphatemia is observationally and
statistically associated with increased cardiovascular
mortality among dialysis patients. Dietary restriction of
phosphate and current dialysis modalities are not sufficiently
effective to maintain serum phosphate levels within the
recommended range, so the majority of dialysis patients
require oral phosphate binders. However, the benefits of
achieving the recommended range have yet to be shown
prospectively. Unfortunately, conventional phosphate
binders are not reliably effective and are associated with a
range of limitations and side effects. Aluminum-containing
agents are highly efficient but no longer widely used because
of proven toxicity. Calcium-based salts are inexpensive,
effective, and most widely used, but there is now concern
about their association with hypercalcemia and vascular
calcification. Sevelamer hydrochloride is associated with
fewer adverse effects, but a large pill burden and high cost
are limiting factors to its wider use. Lanthanum carbonate is
another non-aluminum, calcium-free phosphate binder.
Preclinical and clinical studies have shown a good safety
profile, and it appears to be well tolerated and effective in
reducing phosphate levels in dialysis patients; however, it is
similarly expensive. Data on its safety profile over 6 years of
treatment are now published. Achievement of opinion-based
guidelines appears to have become an end in itself. Dialysis
patient outcomes are worse than outcomes for many types of
cancer, yet prospective, outcome-based randomized
controlled trials are not being undertaken for reasons that
are difficult to explain.
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Normal kidneys filter large amounts of organic phosphate of
which more than 90% is reabsorbed by the renal tubules.
Early renal dysfunction not only reduces filtered phosphate
but also decreases tubular resorption, so that urinary
phosphate excretion continues to match gastrointestinal
absorption, and therefore there is little change in serum
phosphate levels. However, as renal function deteriorates
further, this homeostatic mechanism fails, resulting in
progressive hyperphosphatemia.
Despite the absence of interventional randomized con-
trolled trials (RCTs) of phosphate lowering in patients with
chronic kidney disease (CKD), phosphate is now regarded as
a ‘uremic toxin.’1 The demonstration of a statistical
association between serum phosphate and all-cause mortality
in patients on dialysis2 has transformed the phosphate
molecule from a subject of little interest 10 years ago to
‘dialysis enemy number 1’ today. Unfortunately, there is little
evidence that phosphate control has improved significantly
over the past decade, despite the development of numerous
oral phosphate binders. Several factors may have contributed
to this, including the difficulty of adhering to low phosphate
diets and oral phosphate binder prescriptions, on a back-
ground of inadequate phosphate clearance by dialysis. Other
factors such as efficacy, cost, palatability, and safety of
available binders are also important (Table 1). Despite greater
interest in serum phosphate, control remains poor, so that
more than 36% of UK hemodialysis patients have plasma
phosphate greater than 1.8 mmol/l.3 Of equal concern is the
fact that there is no evidence from RCTs that reducing serum
phosphate to a specific level results in improved clinical
outcomes—largely because the appropriate trials have not
been undertaken.4
WHY SHOULD WE TREAT HYPERPHOSPHATEMIA?
Untreated hyperphosphatemia can lead to secondary hyper-
parathyroidism, renal bone disease, and is statistically
associated with vascular calcification, increased morbidity,
and mortality.5–7 Consequently, phosphate control has
become an important therapeutic target in CKD, primarily
in the hope of reducing the risk of vascular calcification and
cardiovascular mortality, although evidence that this is
achievable is lacking. Indeed, Bushinsky8 makes the point
that ‘there are no data demonstrating that a reduction of
serum phosphorus will improve survival’ but also notes that
‘a prudent clinician cannot dismiss the compelling epide-
miologic evidence and will strive to lower serum phosphorus
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in dialysis patients’. Consequently, hyperphosphatemia has
now been added to the list of cardiovascular risk factors seen
in CKD.9
MANAGEMENT OF HYPERPHOSPHATEMIA IN CKD
The three key elements in the management of elevated serum
phosphate are dietary restriction, drug treatment using oral
phosphate binders (see Figure 1), and adequate dialysis.
Dietary phosphate restriction is impractical for many
patients, and a general decline in home cooking skills often
means that supermarkets are indirectly responsible for
patients’ phosphate, sodium, and potassium intake.10,11 In
addition, it can be restricted only to a certain extent without
risking protein malnutrition, particularly in elderly pa-
tients.12 Conventional 4-h, thrice-weekly hemodialysis
removes approximately 1000 mg of phosphate per session,
but this is generally insufficient to maintain phosphate levels
within the recommended targets, even if oral phosphate
intake is significantly restricted. Peritoneal dialysis removes
slightly more than this when averaged over a week, but is still
insufficient.13 Although short-hours daily and slow nocturnal
hemodialysis are much more effective in reducing serum
phosphate levels, logistic, cost, and patient acceptance issues
limit the widespread usage of these modalities.5 Thus, around
90% of dialysis patients continue to need oral phosphate
binders in an effort to control their phosphate levels.
ORAL PHOSPHATE BINDERS
All currently available oral phosphate binders have limita-
tions of one sort or another (Table 2) and available data from
RCTs do not show the superiority of any one binder over
another. Nevertheless, there has been a progressive evolution
of oral binders from aluminum, through calcium salts, and
on to newer agents such as sevelamer and lanthanum
carbonate. The expense of the newer agents is such that it
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Figure 1 | Effects of oral phosphate binders.
Table 2 | Comparison of oral phosphate binders in general
use
Phosphate
binder Advantages Disadvantages
Aluminum
salts
High efficacy regardless
of pH
Inexpensive
Aluminum toxicity
No definite safe dose
Frequent monitoring
needed
Calcium
carbonate
Aluminum free
Moderately effective
Moderate pill burden
Inexpensive
Efficacy influenced
by pH
Unpalatable
Hypercalcemia
Gastrointestinal
side effects
Possible ectopic
calcification
Calcium
acetate
Aluminum free
Efficacy somewhat
pH dependent
Fairly inexpensive
Lower calcium load
than carbonate
Large tablets need
to be swallowed
Hypercalcemia
Gastrointestinal
side effects
Possible ectopic
calcification
Magnesium
salts
Moderate pill burden
Calcium and aluminum free
Moderate efficacy
Moderate pill burden
Gastrointestinal
side effects
Not widely used
Magnesium
monitoring
Sevelamer Calcium and aluminum free
No gastrointestinal tract
absorption
Moderate efficacy
Reduces total and low-density
lipoprotein cholesterol
Expensive
Efficacy influenced
by pH
High pill burden
Gastrointestinal
side effects
Binds fat-soluble
vitamins
Lanthanum
carbonate
Calcium and aluminum free
Chewed, not swallowed whole
High efficacy regardless of pH
Low pill burden
Expensive
Gastrointestinal
side effects
Minimal
gastrointestinal
absorption
Magnesium
iron
hydroxycarbonate
Calcium and aluminum free
Releases magnesium—
beneficial? (Little published
data)
Gastrointestinal
side effects
Releases magnesium
—effect unknown
Table 1 | Ideal characteristics of an oral phosphate binder
High affinity for binding phosphate—low dose (pill burden) required
Rapid phosphate binding regardless of ambient pH
Low solubility
Little to no systemic absorption
Non-toxic and without side effects
Solid oral dose form
Palatable (encourages compliance)
Inexpensive
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is essential that the nephrology community organizes
appropriate trials to show the benefits of phosphate
reduction and the relative merits of oral binders versus
alternative therapeutic strategies.
ALUMINUM SALTS
Aluminum-based phosphate binders came into general use in
the 1970s. They are still used on a small scale as they are
highly effective, but are associated with cognitive distur-
bances, osteomalacia, and anemia.14,15 Aluminum success-
fully reduces serum phosphate levels through two
mechanisms. First, aluminum hydroxide is able to form
coordination compounds with phosphate ions, and thus ‘trap
and mask’ phosphate ions in the blood. Second, aluminum
ions form aluminum phosphate precipitates in the gut, which
are insoluble and cannot be absorbed. No safe dose of
aluminum has been identified, and dialysis patients who take
it even in modest doses have been reported to develop clinical
evidence of toxicity.16–19 Nonetheless, aluminum salts are still
used as short-term ‘salvage’ therapy to achieve acute control
of high phosphate levels, and are also used in patients whose
prognosis is felt to be so short, because of other comorbid-
ities, that the advantages may outweigh the risks.
Other oral phosphate binders, such as cerium oxide,20
were examined in the 1980s as the toxicity of aluminum came
to light, but the discovery that calcium carbonate was
effective and inexpensive meant that very few were developed
further.
CALCIUM AND MAGNESIUM SALTS
Calcium-based binders (acetate and carbonate) bind phos-
phate ionically and are effective21 and inexpensive, but their
administration results in hypercalcemia in up to 50% of
patients, especially when co-administered with vitamin D
analogs.22 In addition, they can result in over-suppression of
parathyroid hormone and the development of adynamic
bone.23 They have been associated statistically with both soft
tissue and vascular calcification,24 but remain in widespread
use, primarily because of their combination of efficacy and
low cost. Although now blamed by many for accelerating
vascular calcification, it is worth remembering that vascular
calcification was first seen in the 1960s when aluminum
hydroxide was the only commonly available phosphate
binder.25 Calcium acetate is generally accepted to be more
effective in binding intestinal phosphate, per mmol of
administered elemental calcium, than calcium carbonate.26–29
Compliance and tolerability of calcium acetate are possibly
less good, and the studies showing a greater reduction in
mean serum phosphate level, compared with the same dose
of calcium carbonate, were relatively short-term but also
examined cost-benefit and reported an advantage compared
with sevelamer.30
Other calcium-containing binders that are much less
widely used include calcium alginate (25% elemental Ca)31,32
and calcium lactate (12%).33 Calcium ketoglutarate is a
semisynthetic analog of the amino acid glutamic acid that
exerts phosphate-binding properties, apparently without
inducing hypercalcemia.34–36
Reduction of dialysis fluid calcium concentration was
shown to permit administration of increased doses of
calcium carbonate resulting in better phosphate control
without worsening hypercalcemia in peritoneal dialysis
patients.37 A number of similar studies have examined the
serum effects of alteration of dialysate calcium concentration,
but very few directly measure calcium balance, and there are
no recent analyses in the CKD stage 3 or 4 population.
In health, a balanced diet provides 12–30 mmol of calcium
per day, but varying amounts are absorbed by the intestines
under the influence of vitamin D. Normal urinary calcium
excretion varies from 2.5 to 7.5 mmol/day, with the balance
appearing in the feces.38 Total body calcium ranges from 1.0
to 1.5 kg (or about 1.5% of total body weight), of which 99%
is stored in the bones. A 1.25 g tablet of calcium carbonate
contains 12.5 mmol of elemental calcium, so that as CKD
progresses toward dialysis and serum phosphate rises, the
addition of four calcium carbonate tablets per day provides
an additional 50 mmol of elemental calcium.
In a study of dialysis patients with low 1,25-dihydrox-
yvitamin D3 levels, calcium absorption rate was subnormal
in 18 of 19 subjects, with fractional absorption at 120 min
ranging from as low as 3.2 up to 24% of the oral dose.39
Presumably in the presence of an oral vitamin D analog, this
percentage would increase significantly. Therefore, in an
anuric dialysis patient prescribed oral vitamin D and with a
daily calcium ingestion of 60 mmol, one would anticipate
around 15 mmol absorption and no urinary losses. Hemo-
dialysis against a dialysate calcium of 1.25 mmol might
remove 5–12.5 mmol per session, or 2–5 mmol/day when
averaged over 1 week40 giving a potential daily positive
calcium balance of 10–13 mmol (400–520 mg). If skeletal
metabolism is normal, much of the balance may be stored
there, but in the presence of an adynamic skeleton this may
be impossible.
The arguments around the continued use of calcium-
based binders were clearly and forcefully set out in 2006 by
Friedman,41 and Moe and Chertow.42 Friedman argues that
the evidence against calcium is inconclusive and does not
outweigh its financial cost, whereas Moe and Chertow42
argue that vascular calcification is a cell-mediated process
accelerated by hyperphosphatemia and excess calcium load,
and that in prospective, randomized studies, calcium-based
phosphate binders lead to increased arterial calcification.
Sadly, it is not possible at present to know definitively which
opinion is correct, because the evidence on both sides is
inconclusive, and firm evidence does not exist. Friedman43
rightly calls for a ‘head-to-head prospective trial of phosphate
binders in which all other circumstances are held constant,
overseen by a supervisory committee with no investigator
commercial links to study drugs’. Were there not such a large
price differential between calcium and non-calcium-contain-
ing binders, such a trial would probably be unnecessary, and
many clinicians would simply err on the side of caution, as
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advised by Bushinsky8 who comments that ‘normalizing
serum phosphorus in dialysis patients without adding
calcium seems most prudent’. However, from a financial
viewpoint, this option is simply not available to the majority
of patients being managed within cash-limited health-care
systems. As a result, in many countries the debate cannot
focus purely on clinical issues when incontrovertible evidence
is lacking. Furthermore, the cost of such a trial will be large.
Following the negative result of the Dialysis Clinical
Outcomes Revisited44 (DCOR) trial, it is unlikely that a
pharmaceutical company would wish to fund it, and any
result would be open to charges of bias. However, it would
be well within the scope of a national funding body such as
the NIH.
Magnesium-containing phosphate binders can be used as
an alternative to calcium-based agents but are generally less
effective. They are associated with increased serum magne-
sium levels and diarrhea.45,46 O’Donovan et al.47 used
magnesium carbonate in 28 patients for 2 years as a
substitute for aluminum hydroxide. Magnesium carbonate
was administered in doses of 21–63 mmol/day for the pre-
study period and dialysate Mg concentration was changed
from 0.85 mmol/l to low magnesium dialysate (0.25 mmol/l).
Subsequently, a significant drop in predialysis aluminum
levels was observed and serum phosphate was controlled and
remained unchanged from previous levels. Magnesium levels
remained between 1.01 and 1.33 mmol/l. All patients seemed
to tolerate magnesium carbonate well. Despite a number
of similar studies in the 1980s, magnesium salts are not
widely used, but recently interest in them has revived45
because of the possible beneficial effect of magnesium on
vascular health.
Magnesium is predominantly an intracellular cation with
an important role in cellular physiology. Serum levels are
often slightly elevated in dialysis patients.48 and are
influenced by the concentration of dialysate magnesium.49,50
Retrospective studies suggest that magnesium may prevent
vascular calcification in dialysis patients, although this
remains controversial and has not been evaluated prospec-
tively.51,52 Magnesium may reduce arrhythmias postopera-
tively, and although it may theoretically reduce arrhythmic
death in dialysis patients, this hypothesis has never been
tested. Short-term or adjuvant use of magnesium carbonate
appears safe and effective as a phosphate binder, but more
studies are needed to evaluate the long-term effects on
vascular calcification, bone histology, and mortality. Lower
levels of serum magnesium have been recently associated with
the presence of vascular calcification in hemodialysis
patients,53 and another recent study has shown that oral
magnesium supplementation improves carotid intima media
thickness in hemodialysis patients.54
In the search for other alternatives to calcium-containing
binders, a variety of unusual compounds has been examined
including zirconyl chloride octahydrate.55 The same author
was the first to propose a salt of lanthanum as another
possible phosphate binder.56
SEVELAMER HYDROCHLORIDE AND CARBONATE
Sevelamer hydrochloride was the first synthetic non-alumi-
num and calcium-free phosphate binder to become commer-
cially available. It was originally developed to lower plasma
lipids and also has this beneficial side effect in CKD
patients.57 Sevelamer is an aluminum and calcium-free
non-absorbed poly (allylamine hydrochloride) polymer. It
contains multiple amines separated by one carbon from the
polymer backbone. These amines become partially proto-
nated in the intestine and interact with phosphate ions
through ionic and hydrogen bonding. In several open-label
studies, sevelamer appears as effective as calcium-based
binders in lowering phosphate, but without the tendency to
promote hypercalcemia.58 Furthermore, there is some
evidence that sevelamer hydrochloride can attenuate cor-
onary and aortic calcification compared with calcium-based
phosphate binders.59 Despite these advantages, gastrointest-
inal disturbances, metabolic acidosis, and cost are limiting
factors affecting the wider use of sevelamer hydrochloride.60
Unfortunately, the large pill burden required to achieve target
phosphate levels can adversely affect patient adherence. A
large prospective randomized study of sevelamer versus
calcium binders was undertaken in an effort to show reduced
mortality (the DCOR study), but unfortunately the 2-year
trial produced a negative result,44 and it remains unclear
whether this represents methodological problems in the
design and execution, or a genuine result. The results
(Table 3) were originally presented at the 2005 ASN Renal
week as ‘a non-significant 9% reduction in all-cause
mortality with sevelamer relative to the calcium-binder
group (P¼ 0.30)’. Whether a nonsignificant change can be
considered as a reduction is doubtful. However, a subsequent
post hoc analysis of subgroups suggested a survival
advantage for patients aged over 65 years, but the statistical
and clinical validity of this finding remains controversial.61
More recently, St Peter et al.62 conducted a secondary analysis
and found that treatment with sevelamer versus calcium-
based binders did not affect overall mortality (primary
outcome), cause-specific mortality, morbidity, or first or
cause-specific hospitalization (secondary outcomes), but
there was evidence for a small but beneficial effect on the
secondary outcomes of multiple all-cause hospitalizations
(1.7 versus 1.9 admissions/patient-year; P¼ 0.02 adjusted)
and hospital days (12.3 versus 13.9 days/patient-year;
P¼ 0.03 adjusted).
The use of sevelamer does not completely abolish
hypercalcemia, but different studies have produced widely
variable results, presumably reflecting differences in diet,
vitamin D dosage, and dialysate calcium concentrations.
Qunibi et al.30 report no hypercalcemia with sevelamer in the
CARE study, compared with 2–9% with calcium acetate.
However, the sevelamer group experienced a 7–24% in-
cidence of hypocalcemia compared with 2–13% incidence in
the calcium acetate group. In marked contrast, Asmus et al.63
reported 26 and 6% of patients on sevelamer experiencing
calcium levels greater than 10.4 and 11.2 mg per 100 ml,
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respectively, compared with 54 and 27% in the calcium
carbonate group (Table 4).
Many studies undertaken with sevelamer have been
designed to assess its superiority to older calcium-based
phosphate binders.67,68 The RIND study went beyond
biochemical targets to look prospectively at effects on
coronary artery calcification but was unable to show effects
on mortality. At start of dialysis, around one-third of patients
had little evidence of calcification and did not develop any,
after 12- to 18-month follow-up, regardless of the type of oral
phosphate binder prescribed. However, those patients with
calcification at baseline appeared to progress more rapidly if
using calcium-based binders rather than sevelamer. Unfortu-
nately, this type of study raises as many questions as it
answers.
A more recent formulation of sevelamer—as a carbonate—
has recently been approved for use, and appears to solve the
problem of mild acidosis associated with sevelamer hydro-
chloride.69
LANTHANUM CARBONATE
Lanthanum carbonate became available in the United States
in 2005 and in the EU in 2006. Preclinical animal studies
suggested that lanthanum might be similar to aluminum in
phosphate binding capacity but with a more favorable safety
profile. As a trivalent cation, it binds phosphate ionically,
and similar to sevelamer it is a non-aluminum-,
non-calcium-based binder, but with low systemic absorption.
The small fraction of the oral dose that is absorbed
(o0.0013%) undergoes binding to proteins in the plasma
and also biliary excretion after transiting through the liver
within lysosomes.70–72
In a large prospective randomized European multicentre
open-label comparator trial, the efficacy of lanthanum
carbonate was compared with calcium carbonate.66 In total,
around 800 patients were randomized (533 to lanthanum and
267 to calcium carbonate). The primary end point was
reduction of serum phosphate levels to p1.8 mmol/l. After 9
weeks of treatment, both groups had serum phosphate levels
of around 1.69 mmol/l. The proportion of patients achieving
controlled phosphate levels of o1.8 mmol/l was similar in
both treated groups (lanthanum 65.8%, calcium 63.9%) at
the end of the maintenance phase. Perhaps most importantly
from a clinical perspective, there was a significantly lower
incidence of hypercalcemia in the lanthanum group (0.4%)
than in the calcium-treated group (20.2%), as one would
expect with a non-calcium-based binder. The relative potency
of lanthanum carbonate as a binder translates into a reduced
pill burden that may aid patient adherence to therapy.73
In the same way that the use of sevelamer does not abolish
hypercalcemia, the use of lanthanum not reduce the risk to
zero either. Studies document hypercalcemia being reported
as an adverse event in 0.4, 0.6, and 4.3% of subjects taking
lanthanum carbonate monotherapy; however, the incidence
of single transient episodes not regarded by the clinician as
‘adverse’ is much higher, at up to 37% in one long-term
observational study.64 Similarly, hypocalcemia reported as an
adverse event was seen in 3.1 and 7.0% of patients in long-
term studies (Table 4).
Concerns have been expressed about the long-term safety
of lanthanum carbonate in dialysis patients, with regard to
bone and liver toxicity.74 However, reports of its use over 1
year, 3 years, and most recently 6 years appear to have shown
a satisfactory long-term safety profile, with no evidence of
harmful side effects.64,75,76 More recently, a speculative
comparison has been made between lanthanum and
gadolinium with the suggestion that it might have the
potential to cause nephrogenic fibrosing dermopathy.77
However, the serum levels achieved after a dose of
intravenous gadolinium are of the order of 400,000 times
those seen after long-term oral treatment with lanthanum,
which in addition is highly protein bound.78 Furthermore,
free gadolinium is known to be toxic to tissues and has to be
sequestered to make it safe for clinical use by binding to
organic chelates to form stable complexes.79 In contrast, there
is no evidence of similar toxicity with lanthanum. De Broe
concluded that these ‘two trivalent cations differ substantially
in their metabolism, pharmacokinetics, and most impor-
tantly their clinical use and toxicity.’
MAGNESIUM IRON HYDROXYCARBONATE
Magnesium iron hydroxycarbonate is another new oral
phosphate binder currently undergoing clinical trials, with
promising results presented in abstract form only, so far.80 Its
use is associated with increased serum magnesium levels, the
effect of which on bone function is currently unknown.
Table 3 | Dialysis Clinical Outcomes Revisited trial: primary
end point (all-cause mortality)44
End point Sevelamer Calcium binders Relative risk (95%)
Deaths, n (%) 265 (26) 274 (27) 0.91 (0.77–1.08)
Mortality incidence rate
(per 100 patient-years)
15.02 16.15
Table 4 | Reported incidence of hyper and hypocalcemia in
studies of sevelamer hydrochloride and lanthanum
carbonate
Hypercalcemic patients
(%)
Hypocalcemic patients
(%)
Sevelamer
Asmus et al.63 26 (410.4 mg per 100 ml) NR
6 (411.2 mg per 100 ml)
Qunibi et al.30 0 7–24
Bleyer et al.58 5 NR
Lanthanum
Hutchison et al.64 0.6 3.1
Finn65 4.3 7.0
Hutchison et al.66 0.4 1.9
Note: Precise definitions of hyper/hypocalcemia vary or are not specified in these
publications, which therefore may not be directly comparable. NR denotes data not
reported in the manuscript.
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However, it is clear that hypomagnesemia is associated with
reduced bone mineral density in both rats and humans,81–84
and hypermagnesemia has been associated with reduced
vascular calcification,51 so this may be beneficial. On the
other hand, hypermagnesemia has also been associated with
adynamic bone85 and there are rare reports of it causing
quadriparesis and even death in extreme cases.86,87
GASTROINTESTINAL PHOSPHATE ABSORPTION BLOCKADE
Over 10 years ago, Katai et al.88 showed that nicotinamide
could inhibit sodium-dependent phosphate co-transport
activity in the rat small intestine, but it was not until 2004
that another Japanese group used oral nicotinamide in a
group of 65 hyperphosphatemic dialysis patients.89 These
patients discontinued their existing oral phosphate binder
therapy allowing serum levels to rise, and then commenced
oral nicotinamide at a mean dose of 1080 mg daily. Over a
12-week follow-up period, serum phosphate levels returned
to their pre-study level of around 5.4 mg per 100 ml, with no
effect on serum calcium and a beneficial rise in serum high-
density lipoprotein plus a fall in low-density lipoprotein. The
authors proposed that nicotinamide could be a useful
alternative method of controlling serum phosphate, but it
seems possible that it could also be used as an additive
treatment. Similar findings were described by Eto et al.90 in rats
with renal failure. Gastrointestinal side effects are likely to limit
the dosage of nicotinamide, but the blockade or inhibition of
the intestinal transport mechanism by alternative molecules is
an attractive possibility. Interestingly, fructose has very recently
been described as having this effect.91
PATIENT EDUCATION TO ASSIST CONTROL OF SERUM
PHOSPHATE
The quantity of information that dialysis patients need to
understand, to participate in their own management is
substantial. No other current medical intervention requires
such detailed knowledge of fluid balance, dietary control,
medication timing, and dosage, plus the dialysis process itself
for a ‘home dialyzer.’ Few medical staff or nurses have
additional qualifications in teaching, yet there seems little
doubt that time spent with the patient is beneficial and
several studies have shown that patient education programs
are associated with an improvement in serum phosphate
control,92–94 although repeated reinforcement is required.95
Most adults are aware of the importance of controlling blood
pressure, cholesterol, and body mass index, even if they do
not have any illness. However, they are very unlikely to have
come across any public health messages concerning phos-
phate, and therefore it is incumbent on the CKD team to
provide appropriate education. Where this has been trialed,
the results have been encouraging, particularly where easily
understood visual aids have been used.96
WHERE DO WE GO FROM HERE?
‘Figures often beguile me,’ Mark Twain wrote, ‘particularly
when I have the arranging of them myself ’.97 Sadly, it seems
that the nephrology community is currently beguiled in a
similar manner. Observational studies have produced nu-
merous statistical associations, which have in turn given rise
to a multitude of opinion-based guidelines. Although the
authors of the K/DOQI guidelines clearly stated that ‘Since
the majority of the recommendations made in this set of
guidelines are based on opinion, it is imperative that
evaluation of their clinical outcomes be made a component
of their implementation.’98 We have collectively failed to do
so. Consequently, although we know that high serum
phosphate levels are associated with increased risk of death,
there is no incontrovertible evidence that reducing serum
phosphate levels will prolong life.8
The likelihood of 5-year survival on dialysis, for a 60-year-
old patient in Europe and the United States, is currently
around 46–50%, which is only marginally better than that of
a similar aged woman with ovarian carcinoma (45%).99
Furthermore, an ovarian cancer survivor at 5 years is likely to
have been cured, whereas the mortality associated with
dialysis continues relentlessly. Nevertheless, nephrologists are
content to spend ever increasing amounts of money on
expensive pharmaceutical agents with little evidence that they
will improve survival or quality of life.
The reasons for this parlous state of affairs are numerous
and complex. First, licensing authorities such as the US Food
and Drug Administration and the European Medicines
Agency generally do not require outcome studies for
approval. They are focused on safety and efficacy. By
publishing guidelines with biochemical targets, nephrology
has provided the standard by which to judge efficacy – yet no
cancer drug would be assessed in this manner. Second, RCTs
are difficult to conduct in nephrology because they require
multicenter cooperation and long duration of follow-up,
with significant associated expense. Such studies would need
to be organized with the cooperation and funding of large
pharmaceutical companies. However, it is not in their
interests to do this so long as we are content to keep
prescribing new and ever more expensive agents, in a vain
effort to achieve self-imposed (albeit pharma sponsored100)
biochemical targets.101 To make matters worse, our guide-
lines limit or prohibit the use of older and cheaper agents
such as calcium carbonate and acetate – largely on the basis of
observation and opinion. Third, we seem to repeatedly ask
the wrong whether one oral phosphate binder is better than
another is only relevant when we can show that lowering
serum phosphate, and to what extent, will improve clinical
outcomes.102,103
It seems unlikely that an ethics review board would
sanction a trial of a phosphate binder versus placebo with an
unlimited upper level of phosphate, but it would be
reasonable to test the theory that controlling serum
phosphate to a range of 3.0–4.5 mg/dL per 100 ml might be
advantageous compared with 6.5–8.0 mg/dL. Which specific
binder one would use for such a study is a difficult question.
Ideally, one would want four groups – calcium, and high
phosphate, non-calcium, and high phosphate – but this
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would add considerably to the cost and complexity of the
trial and would probably preclude sponsorship from
pharmaceutical companies at least.
CONCLUSION
Hyperphosphatemia is prevalent in the dialysis population
and is considered by many to be an independent risk factor
associated with cardiovascular morbidity and mortality. Its
control remains a challenging issue for clinical nephrologists
because none of the traditional therapeutic approaches
appear entirely satisfactory. Dietary restrictions are difficult
to follow and standard hemodialysis is inadequate for
removal of phosphate, so that the vast majority of dialysis
patients require oral phosphate binders. Until recently, none
of the available agents fulfilled the criteria of an ideal
phosphate binder. Aluminum- and calcium-based binders
have numerous drawbacks, but are inexpensive.
The introduction of sevelamer hydrochloride, and subse-
quently of lanthanum carbonate, represent significant devel-
opments in phosphate management. Both are non-
aluminum, calcium-free agents, but are expensive. Sevelamer
achieves effective phosphate lowering and may attenuate
progression of vascular calcification in hemodialysis patients.
Lanthanum carbonate represents another step on the way to
complete phosphate control. Evidence suggests that it is an
effective, well tolerated, and safe phosphate binder. Patient
education programs have been shown to be an effective
adjunct to other methods of phosphate control.
Sadly, randomized prospective outcome studies of the
benefits of reducing serum phosphate have yet to be
undertaken, and the achievement of targets set by opinion-
based guidelines seem to have become accepted ‘outcomes’ in
themselves. It is to be hoped that the eagerly awaited KDIGO
CKD-MD guidelines will acknowledge the lack of good
quality data, and stimulate high quality RCT-based research,
rather than a plethora of publications that seek only to
measure the achievement of biochemical targets. If so,
perhaps we can really begin to understand first the role of
serum phosphate, and second, that of oral phosphate binders,
in the management of patients with CKD.
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